Study Number:

Study Gender:

PWG Approval Date

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged

Test Compound: Sodium Metavanadate CAS Number: 13718-26-8 Date Report Requested: 09/02/2020 Time Report Requested: 10:29:55 Lab: Burleson Research Technologies

194043

Female

See web page for date of PWG Approval

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged

Test Compound: Sodium Metavanadate

CAS Number: 13718-26-8

Date Report Requested: 09/02/2020 Time Report Requested: 10:29:55 Lab: Burleson Research Technologies

	Female: Immunopath						
	Treatment Groups (ppm)						
	0	31.3	62.5	125	250	500	
Disposition Summary Animals Initially In Study Scheduled Sacrifice Early Deaths Survivors	8	8	8	8	8	8	
Scheduled sacrifice, terminal (SD 28)	8	8	8	8	8	8	
Animals Examined Microscopically	8	8	8	8	8	8	
ALIMENTARY SYSTEM							
LIVER	(8)	(8)	(8)	(8)	(8)	(8)	
CARDIOVASCULAR SYSTEM No Tissues/Organs Examined							
ENDOCRINE SYSTEM ADRENAL GLAND, RIGHT	(8)	(8)	(8)	(8)	(8)	(8)	
GENERAL BODY SYSTEM No Tissues/Organs Examined							
GENITAL SYSTEM							
COAGULATING GLAND	(1)	(0)	(0)	(0)	(0)	(0)	
HEMATOLYMPHOID SYSTEM							
BALT	(8)	(8)	(8)	(8)	(8)	(8)	
BONE MARROW	(8)	(8)	(8)	(8)	(8)	(8)	
LYMPH NODE, MESENTERIC	(8)	(8)	(8)	(8)	(8)	(8)	
LYMPH NODE, POPLITEAL	(8)	(8)	(8)	(8)	(8)	(8)	
SPLEEN	(8)	(8)	(8)	(8)	(8)	(8)	
THYMUS	(8)	(8)	(8)	(8)	(8)	(8)	

Study Number: 194043 Test Type: TOX Route: Dosing in Water Species/Strain: Mouse/B6C3F1/N	PA05: Incidence Rates of Test	Date Report Requested: 09/02/2020 Time Report Requested: 10:29:55 Lab: Burleson Research Technologies				
	F	emale: Immunopath	I			
	Treatment Groups (ppm)					
	0	31.3	62.5	125	250	500
MUSCULOSKELETAL SYSTEM No Tissues/Organs Examined						
NERVOUS SYSTEM No Tissues/Organs Examined						
RESPIRATORY SYSTEM	(8)	(8)	(8)	(8)	(8)	(8)
SPECIAL SENSES SYSTEM No Tissues/Organs Examined						
URINARY SYSTEM KIDNEY KIDNEY, RIGHT	(1) (8)	(0) (8)	(0) (8)	(0) (8)	(0) (8)	(0) (8)
No Systemic Lesions						

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged

Test Compound: Sodium Metavanadate

CAS Number: 13718-26-8

Date Report Requested: 09/02/2020 Time Report Requested: 10:29:55 Lab: Burleson Research Technologies

Tumor Summary Data for Female Immunopath	Treatment Groups (ppm)							
	0	31.3	62.5	125	250	500		
Total Animals with Primary Neoplasms	0	0	0	0	0	0		
Total Primary Neoplasms	0	0	0	0	0	0		
Total Animals with Benign Neoplasms	0	0	0	0	0	0		
Total Benign Neoplasms	0	0	0	0	0	0		
Total Animals with Malignant Neoplasms	0	0	0	0	0	0		
Total Malignant Neoplasms	0	0	0	0	0	0		
Total Animals with Metastatic Neoplasms	0	0	0	0	0	0		
Total Metastatic Neoplasms	0	0	0	0	0	0		
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0	0	0	0		

Date Report Requested: 09/02/2020 Time Report Requested: 10:29:55 Lab: Burleson Research Technologies

LEGEND

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

Systemic lesions are included once in the total lesion count regardless of how many times they occurred in a single animal

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD – Study Day

** END OF REPORT **